[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
Early triple-negative breast cancer
Metabolic tumor burden
Neoadjuvant chemotherapy ± pembrolizumab
Pathologic response
Tumor metabolism
[18F]FDG PET/CT
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
22
05
2023
accepted:
08
08
2023
medline:
30
10
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
ppublish
Résumé
To determine if pretreatment [18F]FDG PET/CT could contribute to predicting complete pathological complete response (pCR) in patients with early-stage triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy with or without pembrolizumab. In this retrospective bicentric study, we included TNBC patients who underwent [18F]FDG PET/CT before neoadjuvant chemotherapy (NAC) or chemo-immunotherapy (NACI) between March 2017 and August 2022. Clinical, biological, and pathological data were collected. Tumor SUVmax and total metabolic tumor volume (TMTV) were measured from the PET images. Cut-off values were determined using ROC curves and a multivariable model was developed using logistic regression to predict pCR. N = 191 patients were included. pCR rates were 53 and 70% in patients treated with NAC (N = 91) and NACI (N = 100), respectively (p < 0.01). In univariable analysis, high Ki67, high tumor SUVmax (> 12.3), and low TMTV (≤ 3.0 cm High tumor metabolism (SUVmax) and low tumor burden (TMTV) could predict pCR after NAC regardless of the addition of pembrolizumab. Further studies are warranted to validate such findings and determine how these biomarkers could be used to guide neoadjuvant therapy in TNBC patients.
Identifiants
pubmed: 37606858
doi: 10.1007/s00259-023-06394-y
pii: 10.1007/s00259-023-06394-y
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
pembrolizumab
DPT0O3T46P
BRCA1 protein, human
0
BRCA1 Protein
0
Radiopharmaceuticals
0
BRCA2 protein, human
0
BRCA2 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4024-4035Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.
doi: 10.1056/NEJMra1001389
pubmed: 21067385
Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485–505.
doi: 10.1200/JCO.20.03399
pubmed: 33507815
pmcid: 8274745
Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497–508.
doi: 10.1093/annonc/mdy127
pubmed: 29873695
Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381.
doi: 10.1136/bmj-2021-066381
pubmed: 34933868
pmcid: 8689398
Telli M. Evolving treatment strategies for triple-negative breast cancer. J Natl Compr Canc Netw. 2015;13:652–4.
doi: 10.6004/jnccn.2015.0194
pubmed: 25995421
Sharma P, López-Tarruella S, García-Saenz JA, Khan QJ, Gómez HL, Prat A, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res. 2018;24:5820–9.
doi: 10.1158/1078-0432.CCR-18-0585
pubmed: 30061361
pmcid: 6279513
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.
doi: 10.1056/NEJMoa1910549
pubmed: 32101663
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556–67.
doi: 10.1056/NEJMoa2112651
pubmed: 35139274
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6:676–84.
doi: 10.1001/jamaoncol.2019.6650
pubmed: 32053137
Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33:534–43.
doi: 10.1016/j.annonc.2022.02.004
pubmed: 35182721
Ahmed FS, Gaule P, McGuire J, Patel K, Blenman K, Pusztai L, et al. PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2020;26:5456–61.
doi: 10.1158/1078-0432.CCR-20-1303
pubmed: 32709714
pmcid: 7572612
Balibegloo M, Nejadghaderi SA, Sadeghalvad M, Soleymanitabar A, SalehiNezamabadi S, Saghazadeh A, et al. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: a systematic review and meta-analysis. Int Immunopharmacol. 2021;96: 107796.
doi: 10.1016/j.intimp.2021.107796
pubmed: 34162158
Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, et al. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE. 2019;14:e0216954.
doi: 10.1371/journal.pone.0216954
pubmed: 31086392
pmcid: 6516638
Humbert O, Riedinger J-M, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V, et al. Identification of biomarkers including 18FDG-PET/CT for early prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2015;21:5460–8.
doi: 10.1158/1078-0432.CCR-15-0384
pubmed: 26130460
Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, et al. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:377–85.
doi: 10.1007/s00259-014-2941-1
pubmed: 25432784
Urso L, Evangelista L, Alongi P, Quartuccio N, Cittanti C, Rambaldi I, et al. The value of semiquantitative parameters derived from 18F-FDG PET/CT for predicting response to neoadjuvant chemotherapy in a cohort of patients with different molecular subtypes of breast cancer. Cancers (Basel). 2022;14:5869.
doi: 10.3390/cancers14235869
pubmed: 36497351
Amin MB, Greene F, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.
doi: 10.3322/caac.21388
pubmed: 28094848
Masuda H, Masuda N, Kodama Y, Ogawa M, Karita M, Yamamura J, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol. 2011;67:911–7.
doi: 10.1007/s00280-010-1371-4
pubmed: 20593180
Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.
doi: 10.1016/S1470-2045(17)30904-X
pubmed: 29233559
Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, et al. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res. 2020;22:69.
doi: 10.1186/s13058-020-01303-9
pubmed: 32576238
pmcid: 7310491
Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217–26.
doi: 10.1056/NEJMoa2202809
pubmed: 35857659
Chae S, Kang KM, Kim HJ, Kang E, Park SY, Kim JH, et al. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. Curr Oncol. 2018;25:e113–9.
doi: 10.3747/co.25.3888
pubmed: 29719435
pmcid: 5927790
Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:77–102.
doi: 10.6004/jnccn.2021.0001
pubmed: 33406487
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
doi: 10.1007/s00259-014-2961-x
pubmed: 25452219
Frelau A, Palard-Novello X, Jali E, Boussemart L, Dupuy A, James P, et al. Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. Cancer Immunol Immunother. 2021;70:679–87.
doi: 10.1007/s00262-020-02712-7
pubmed: 32880684
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217–38.
doi: 10.1016/j.annonc.2022.10.001
pubmed: 36270461
Yamashita N, Long M, Fushimi A, Yamamoto M, Hata T, Hagiwara M, et al. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. J Immunother Cancer. 2021;9:e002115.
doi: 10.1136/jitc-2020-002115
pubmed: 33495298
pmcid: 7839859
Gao S, Tang W, Zuo B, Mulvihill L, Yu J, Yu Y. The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. Front Oncol. 2022;12:1065606.
doi: 10.3389/fonc.2022.1065606
pubmed: 36727046
Pereira-Veiga T, Bravo S, Gómez-Tato A, Yáñez-Gómez C, Abuín C, Varela V, et al. Red blood cells protein profile is modified in breast cancer patients. Mol Cell Proteomics. 2022;21:100435.
doi: 10.1016/j.mcpro.2022.100435
pubmed: 36519745
pmcid: 9713370
Zhu W, Xu B. Association of pretreatment anemia with pathological response and survival of breast cancer patients treated with neoadjuvant chemotherapy: a population-based study. PLoS ONE. 2015;10:e0136268.
doi: 10.1371/journal.pone.0136268
pubmed: 26291454
pmcid: 4546363
Zhang Z, Zhang F, Yuan F, Li Y, Ma J, Ou Q, et al. Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol. 2020;12:1758835920970049.
doi: 10.1177/1758835920970049
pubmed: 33224276
pmcid: 7649885
Kurashina R, Ando K, Inoue M, Maruyama R, Mitani K, Takenobu H, et al. Pretreatment hemoglobin levels and platelet-to-lymphocyte ratio predict survival benefit from pembrolizumab in advanced urothelial carcinoma. Cancer Diagn Progn. 2023;3:230–5.
doi: 10.21873/cdp.10206
pubmed: 36875313
pmcid: 9949547
Hirakata T, Fujii T, Kurozumi S, Katayama A, Honda C, Yanai K, et al. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. Breast Cancer Res Treat. 2020;181:331–8.
doi: 10.1007/s10549-020-05619-0
pubmed: 32253685
Carter JM, Polley M-YC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, et al. Characteristics and spatially defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer. Clin Cancer Res. 2021;27:5628–37.
doi: 10.1158/1078-0432.CCR-21-0343
pubmed: 34108182
pmcid: 8808363
Kimura Y, Sasada S, Emi A, Masumoto N, Kadoya T, Arihiro K, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography predicts tumor immune microenvironment function in early triple-negative breast cancer. Anticancer Res. 2023;43:127–36.
doi: 10.21873/anticanres.16141
pubmed: 36585209
Murakami W, Tozaki M, Sasaki M, Hida AI, Ohi Y, Kubota K, et al. Correlation between 18F-FDG uptake on PET/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer. Eur J Radiol. 2020;123:108773.
doi: 10.1016/j.ejrad.2019.108773
pubmed: 31918248
Deepak KGK, Vempati R, Nagaraju GP, Dasari VR, Nagini S, Rao DN, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683.
doi: 10.1016/j.phrs.2020.104683
pubmed: 32050092
Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH. 18F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer. J Nucl Med Technol. 2018;46:260–4.
doi: 10.2967/jnmt.117.204933
pubmed: 29599403
Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28:583–9.
doi: 10.1093/annonc/mdw640
pubmed: 27998967